Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 3, member D antisense RNA 1 (FAM3D-AS1) is a conserved long non-coding RNA (lncRNA), predominantly localized in the cytoplasm, which does not encode a protein. It plays a regulatory role in cellular processes such as inhibition of cell proliferation, invasion, and epithelial-mesenchymal transition (EMT), particularly in colorectal cancer. Overexpression of FAM3D-AS1 inhibits tumor-associated behaviors and may reverse EMT via modulation of the NF-κB signaling pathway. There is emerging evidence for its function as a tumor suppressor lncRNA, with decreased expression in colorectal cancer tissues compared to adjacent normal tissues. Its potential relevance in other diseases, such as endometrial cancer, is under study, though there is currently no strong evidence linking it as a risk factor in that context. FAM3D-AS1 is not currently classified as a druggable therapeutic target (like a receptor, enzyme, or transporter), nor are there clinically approved drugs targeting it directly, but it is being explored as a candidate biomarker and novel regulator in cancer biology[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 3, member D antisense RNA 1 (FAM3D-AS1).